{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:16:59Z","timestamp":1792783019363,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["JP16K08563"],"award-info":[{"award-number":["JP16K08563"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10557-019-06900-1","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T03:03:19Z","timestamp":1565924599000},"page":"501-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2044-5552","authenticated-orcid":false,"given":"Satomi","family":"Kagota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Maruyama-Fumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Shimari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Shinozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"key":"6900_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.019","volume":"164","author":"MC Michel","year":"2016","unstructured":"Michel MC, Brunner HR, Foster C, Huo Y. Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. Pharmacol Ther. 2016;164:1\u201381.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"6900_CR2","first-page":"49","volume":"45","author":"P Kizilirmak","year":"2017","unstructured":"Kizilirmak P, Uresin Y, Ozdemir O, Kilickiran Avci B, Tokgozoglu L, Ongen Z. Renin-angiotensin-aldosterone system blockers and cardiovascular outcomes: a meta-analysis of randomized clinical trials. Turk Kardiyol Dern Ars. 2017;45(1):49\u201366.","journal-title":"Turk Kardiyol Dern Ars"},{"key":"6900_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CE.S81776","volume":"11","author":"E Angeloni","year":"2016","unstructured":"Angeloni E. Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy. Core Evid. 2016;11:1\u201310.","journal-title":"Core Evid"},{"issue":"11","key":"6900_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.clinthera.2011.10.007","volume":"33","author":"K Zaiken","year":"2011","unstructured":"Zaiken K, Cheng JW. Azilsartan medoxomil: a new angiotensin receptor blocker. Clin Ther. 2011;33(11):1577\u201389.","journal-title":"Clin Ther"},{"issue":"3","key":"6900_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1124\/jpet.110.176636","volume":"336","author":"M Ojima","year":"2011","unstructured":"Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011;336(3):801\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"6900_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1254\/jphs.13167FP","volume":"123","author":"S Takai","year":"2013","unstructured":"Takai S, Jin D, Sakonjo H, Takubo T, Nakanishi T. Significance of the vascular concentration of angiotensin II-receptor blockers on the mechanism of lowering blood pressure in spontaneously hypertensive rats. J Pharmacol Sci. 2013;123(4):371\u20139.","journal-title":"J Pharmacol Sci"},{"issue":"3","key":"6900_CR7","doi-asserted-by":"publisher","first-page":"e000035","DOI":"10.1161\/JAHA.113.000035","volume":"2","author":"D Sueta","year":"2013","unstructured":"Sueta D, Kataoka K, Koibuchi N, Toyama K, Uekawa K, Katayama T, et al. Novel mechanism for disrupted circadian blood pressure rhythm in a rat model of metabolic syndrome\u2014the critical role of angiotensin II. J Am Heart Assoc. 2013;2(3):e000035.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"6900_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10557-014-6530-0","volume":"28","author":"MA Hye Khan","year":"2014","unstructured":"Hye Khan MA, Neckar J, Cummens B, Wahl GM, Imig JD. Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. Cardiovasc Drugs Ther. 2014;28(4):313\u201322.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8","key":"6900_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/ajh\/hpu016","volume":"27","author":"MA Hye Khan","year":"2014","unstructured":"Hye Khan MA, Neckar J, Haines J, Imig JD. Azilsartan improves glycemic status and reduces kidney damage in zucker diabetic fatty rats. Am J Hypertens. 2014;27(8):1087\u201395.","journal-title":"Am J Hypertens"},{"issue":"1","key":"6900_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.31871\/WJRR.6.1.18","volume":"6","author":"T Takami","year":"2018","unstructured":"Takami T, Okada S, Saito Y, Nishijima Y, Kobori H, Nishiyama A. Effects of olmesartan and azilsartan on albuminuria and the intrarenal renin-angiotensin system. World J Res Rev. 2018;6(1):7\u201310.","journal-title":"World J Res Rev"},{"issue":"5","key":"6900_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.trsl.2014.06.003","volume":"164","author":"M Abdelsaid","year":"2014","unstructured":"Abdelsaid M, Coucha M, Ergul A. Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes. Transl Res. 2014;164(5):424\u201332.","journal-title":"Transl Res"},{"issue":"20","key":"6900_CR12","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1111\/bph.13650","volume":"174","author":"N Xia","year":"2017","unstructured":"Xia N, Li H. The role of perivascular adipose tissue in obesity-induced vascular dysfunction. Br J Pharmacol. 2017;174(20):3425\u201342.","journal-title":"Br J Pharmacol"},{"issue":"20","key":"6900_CR13","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1111\/bph.13705","volume":"174","author":"R Nosalski","year":"2017","unstructured":"Nosalski R, Guzik TJ. Perivascular adipose tissue inflammation in vascular disease. Br J Pharmacol. 2017;174(20):3496\u2013513.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"6900_CR14","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1440-1681.2010.05432.x","volume":"37","author":"S Kagota","year":"2010","unstructured":"Kagota S, Fukushima K, Umetani K, Tada Y, Nejime N, Nakamura K, et al. Coronary vascular dysfunction promoted by oxidative-nitrative stress in SHRSP.Z-Lepr(fa) \/IzmDmcr rats with metabolic syndrome. Clin Exp Pharmacol Physiol. 2010;37(11):1035\u201343.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"5","key":"6900_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1291\/hypres.31.1021","volume":"31","author":"T Ueno","year":"2008","unstructured":"Ueno T, Takagi H, Fukuda N, Takahashi A, Yao EH, Mitsumata M, et al. Cardiovascular remodeling and metabolic abnormalities in SHRSP.Z-Lepr(fa)\/IzmDmcr rats as a new model of metabolic syndrome. Hypertens Res. 2008;31(5):1021\u201331.","journal-title":"Hypertens Res"},{"issue":"1\u20132","key":"6900_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1440-1681.2004.03962.x","volume":"31","author":"J Hiraoka-Yamamoto","year":"2004","unstructured":"Hiraoka-Yamamoto J, Nara Y, Yasui N, Onobayashi Y, Tsuchikura S, Ikeda K. Establishment of a new animal model of metabolic syndrome: SHRSP fatty (fa\/fa) rats. Clin Exp Pharmacol Physiol. 2004;31(1\u20132):107\u20139.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"5","key":"6900_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1089\/met.2016.0146","volume":"15","author":"S Kagota","year":"2017","unstructured":"Kagota S, Iwata S, Maruyama K, McGuire JJ, Shinozuka K. Time-dependent differences in the influence of perivascular adipose tissue on vasomotor functions in metabolic syndrome. Metab Syndr Relat Disord. 2017;15(5):233\u20139.","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"6900_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3390\/ijms20010106","volume":"20","author":"Satomi Kagota","year":"2018","unstructured":"Kagota S, Maruyama-Fumoto K, Iwata S, Shimari M, Koyanagi S, Shiokawa Y, et al. Perivascular adipose tissue-enhanced vasodilation in metabolic syndrome rats by apelin and N-acetyl(\u2212)l-cysteine-sensitive factor(s). Int J Mol Sci. 2018;20(1).","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"6900_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1677\/JOE-07-0284","volume":"197","author":"B Galvez-Prieto","year":"2008","unstructured":"Galvez-Prieto B, Bolbrinker J, Stucchi P, de Las Heras AI, Merino B, Arribas S, et al. Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. J Endocrinol. 2008;197(1):55\u201364.","journal-title":"J Endocrinol"},{"issue":"12","key":"6900_CR20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1463-1326.2011.01471.x","volume":"13","author":"M Zhao","year":"2011","unstructured":"Zhao M, Li Y, Wang J, Ebihara K, Rong X, Hosoda K, et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab. 2011;13(12):1123\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"6900_CR21","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1248\/bpb.29.1756","volume":"29","author":"Y Kubota","year":"2006","unstructured":"Kubota Y, Umegaki K, Kagota S, Tanaka N, Nakamura K, Kunitomo M, et al. Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol Pharm Bull. 2006;29(8):1756\u20138.","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"6900_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1139\/y11-029","volume":"89","author":"S Kagota","year":"2011","unstructured":"Kagota S, Tada Y, Nejime N, Nakamura K, Kunitomo M, Shinozuka K. Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)\/IzmDmcr rats with metabolic syndrome. Can J Physiol Pharmacol. 2011;89(5):355\u201364.","journal-title":"Can J Physiol Pharmacol"},{"key":"6900_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1475-2840-13-30","volume":"13","author":"S Matsumoto","year":"2014","unstructured":"Matsumoto S, Shimabukuro M, Fukuda D, Soeki T, Yamakawa K, Masuzaki H, et al. Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)\/Thr(497) of endothelial nitric oxide synthase in diabetic mice. Cardiovasc Diabetol. 2014;13:30.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"6900_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/10641960902993129","volume":"32","author":"F Huang","year":"2010","unstructured":"Huang F, Lezama MA, Ontiveros JA, Bravo G, Villafana S, del-Rio-Navarro BE, et al. Effect of losartan on vascular function in fructose-fed rats: the role of perivascular adipose tissue. Clin Exp Hypertens. 2010;32(2):98\u2013104.","journal-title":"Clin Exp Hypertens"},{"issue":"1","key":"6900_CR25","first-page":"1753","volume":"17","author":"T Wang","year":"2018","unstructured":"Wang T, Lian G, Cai X, Lin Z, Xie L. Effect of prehypertensive losartan therapy on AT1R and ATRAP methylation of adipose tissue in the later life of highfatfed spontaneously hypertensive rats. Mol Med Rep. 2018;17(1):1753\u201361.","journal-title":"Mol Med Rep"},{"key":"6900_CR26","doi-asserted-by":"publisher","first-page":"946492","DOI":"10.1155\/2014\/946492","volume":"2014","author":"A Maeda","year":"2014","unstructured":"Maeda A, Tamura K, Wakui H, Ohsawa M, Azushima K, Uneda K, et al. Effects of the angiotensin receptor blocker olmesartan on adipocyte hypertrophy and function in mice with metabolic disorders. Biomed Res Int. 2014;2014:946492.","journal-title":"Biomed Res Int"},{"issue":"17","key":"6900_CR27","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.2174\/1381612811319170010","volume":"19","author":"K Tamura","year":"2013","unstructured":"Tamura K, Wakui H, Maeda A, Dejima T, Ohsawa M, Azushima K, et al. The physiology and pathophysiology of a novel angiotensin receptor-binding protein ATRAP\/Agtrap. Curr Pharm Des. 2013;19(17):3043\u20138.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"6900_CR28","doi-asserted-by":"publisher","first-page":"e000312","DOI":"10.1161\/JAHA.113.000312","volume":"2","author":"A Maeda","year":"2013","unstructured":"Maeda A, Tamura K, Wakui H, Dejima T, Ohsawa M, Azushima K, et al. Angiotensin receptor-binding protein ATRAP\/Agtrap inhibits metabolic dysfunction with visceral obesity. J Am Heart Assoc. 2013;2(4):e000312.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"6900_CR29","doi-asserted-by":"publisher","first-page":"646","DOI":"10.7150\/ijms.8577","volume":"11","author":"A Maeda","year":"2014","unstructured":"Maeda A, Tamura K, Wakui H, Ohsawa M, Azushima K, Uneda K, et al. Effects of Ang II receptor blocker irbesartan on adipose tissue function in mice with metabolic disorders. Int J Med Sci. 2014;11(6):646\u201351.","journal-title":"Int J Med Sci"},{"issue":"1\u20133","key":"6900_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejphar.2010.02.006","volume":"634","author":"C Lu","year":"2010","unstructured":"Lu C, Su LY, Lee RM, Gao YJ. Mechanisms for perivascular adipose tissue-mediated potentiation of vascular contraction to perivascular neuronal stimulation: the role of adipocyte-derived angiotensin II. Eur J Pharmacol. 2010;634(1\u20133):107\u201312.","journal-title":"Eur J Pharmacol"},{"key":"6900_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.niox.2018.12.011","volume":"84","author":"N Nobrega","year":"2019","unstructured":"Nobrega N, Araujo NF, Reis D, Facine LM, Miranda CAS, Mota GC, et al. Hydrogen peroxide and nitric oxide induce anticontractile effect of perivascular adipose tissue via renin angiotensin system activation. Nitric Oxide. 2019;84:50\u20139.","journal-title":"Nitric Oxide"},{"issue":"12","key":"6900_CR32","doi-asserted-by":"publisher","first-page":"e0167704","DOI":"10.1371\/journal.pone.0167704","volume":"11","author":"K Tsukuda","year":"2016","unstructured":"Tsukuda K, Mogi M, Iwanami J, Kanno H, Nakaoka H, Wang XL, et al. Enhancement of adipocyte browning by angiotensin II type 1 receptor blockade. PLoS One. 2016;11(12):e0167704.","journal-title":"PLoS One"},{"key":"6900_CR33","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fphys.2018.00400","volume":"9","author":"LR Kong","year":"2018","unstructured":"Kong LR, Zhou YP, Chen DR, Ruan CC, Gao PJ. Decrease of perivascular adipose tissue browning is associated with vascular dysfunction in spontaneous hypertensive rats during aging. Front Physiol. 2018;9:400.","journal-title":"Front Physiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-019-06900-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-019-06900-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-019-06900-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:37:46Z","timestamp":1778492266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-019-06900-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["6900"],"URL":"https:\/\/doi.org\/10.1007\/s10557-019-06900-1","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,16]]},"assertion":[{"value":"16 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Animal Experimentation Committee at Mukogawa Women\u2019s University (protocol numbers: P-12-2016-01-A, P-12-2017-01-A, and P-12-2018-01-A), and all animal experiments were performed in accordance with the guidelines for the Care and Use of Laboratory Animals at Mukogawa Women\u2019s University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All protocols involving the care and use of animals were approved by the animal ethics committee and performed in accordance with the Guidelines for the Care and Use of Laboratory Animals at Mukogawa Women\u2019s University (protocol numbers: P-12-2016-01-A, P-12-2017-01-A, and P-12-2018-01-A).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Animals"}}]}}